Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
Notified -
Globe NewswireYesterday, 19:00
Wellbeing Solutions Leader Workplace Options Hosts Global Burnout Conference 21-06-2023, 23:13